Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Osteologix has announced that the FDA has accepted its investigational new drug application for its lead development candidate NB S101, for the treatment and prevention of osteoporosis.
Subscribe to our email newsletter
NB S101, a dual acting bone agent, has a demonstrated ability to decrease resorption of bone while maintaining formation of new bone. The drug has been formulated as a convenient once-daily tablet.
Philip Young, Osteologix president and CEO, said: “This is an important step in the process of developing this exciting compound and we look forward to working with the agency as we prepare for the next clinical trials.”